Join us in-person for the 2025 DTRF "Together We Will" Weekend in Chicago from Sept. 12-13! - Register Today

The Desmoid Tumor Research Foundation

October 2013

Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors.

Author Information

Aya Fujita,Hidetaka Yamamoto,Junichi Motoshita,Katsumi Arakaki,Katsuya Morimatsu,Kenichi Kohashi,Minako Hirahashi,Yoko Zaitsu,Yoshinao Oda,Yumi Oshiro

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.,Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Electronic address:hidetaka@surgpath.med.kyushu-u.ac.jp.,Department of Pathology, Hamanomachi Hospital, Fukuoka 810-8539, Japan.,Department of Pathology, Matsuyama Red Cross Hospital, Matsuyama 790-8524, Japan.

Publication

Summary

Insulin-like growth factor II messenger RNA-binding protein 3 (IMP3) is a recently identified biomarker demonstrated to be useful in diagnosis and prognostic prediction for several kinds of malignant tumors. In this study, we examined the immunohistochemical expression of IMP3 in gastrointestinal stromal tumor (GIST) (n = 150), malignant melanoma (n = 17), malignant mesothelioma (n = 6), leiomyosarcoma (n = 6), inflammatory myofibroblastic tumor (IMT) (n = 12), desmoid fibromatosis (n = 8), leiomyoma (n = 20), and schwannoma (n = 20). GIST, desmoid fibromatosis, leiomyoma and schwannoma, were essentially negative for IMP3.

View Abstract